Volume: 11, Issue: 2
ABSTRACT
The majority of women who get a breast cancer diagnosis live far into the age of 60, making it the most common illness in the world among female patients. The percentage of elderly women who get breast cancer diagnosis is increasing, as is the average life expectancy. Clinical practice guidelines do not sufficiently address the management of this patient group, and they are under-represented in therapeutic studies. Under treatment is common, mostly as a result of irrational concerns about ageing and associated comorbidities. Oncoplastic surgery and axillary care, however, may be customised according on the patient's unique needs and the specifics of their condition. The majority of targeted therapies, chemotherapeutic drugs, and anti-Human epidermal growth factor receptor-2 (HER2) treatments may be given to elderly patients in a safe manner; careful monitoring of any adverse effects and dose modifications may be required. Adjuvant radiation therapy has been shown to be safe and successful in modifying or even stopping the condition; at least in low-risk elderly adults. The whole range of treatments for breast cancer in the elderly, with a focus on adjuvant chemotherapy, radiation therapy and endocrine therapy during the initial tumour excision process, as well as the care of advanced-stage and recurring illnesses. Future studies on older breast cancer might look at the use of precision medicine techniques created specifically for the elderly. This would include the development of age-specific biomarkers and more accurate genetic profiling techniques to predict the tolerance and response to medication of elderly patients.
Breast Cancer, Oncoplastic Surgery, Chemotherapeutic Drugs, HER2 Treatment, Radiation Therapy, Endocrine Therapy, Adverse Effect